Literature DB >> 25126157

Stereotactic Ablative Radiotherapy (SABR): Impact on the Immune System and Potential for Future Therapeutic Modulation.

Adam S Reese1, Steven J Feigenberg1, Azmat Husain2, Tonya J Webb3, Petr F Hausner4, Martin J Edelman4, Josephine Feliciano4, Katherine H Tkaczuk4, Navesh K Sharma1.   

Abstract

Stereotactic ablative radiotherapy (SABR) has been demonstrated to provide excellent local control in several malignancies. Recent reports have suggested that this ablative dose may impact disease outside of the radiated area. Furthermore, these studies have implicated immune modulation as the primary mechanism of disease response outside the irradiated area. More specifically, T-cell stimulation and tumor necrosis factor-α modulation following high dose irradiation have been suggested as the responsible components of this phenomenon. In addition, the "abscopal effect" may play a role in disease response outside of the radiated area. We review the current literature regarding the effects of ablative radiation therapy, the potential for immune modulation from it, and the mechanisms of the distant effects it elicits.

Entities:  

Keywords:  Ablative Radiotherapy; Immune Response; Therapeutic Modulation

Year:  2013        PMID: 25126157      PMCID: PMC4128167     

Source DB:  PubMed          Journal:  Mol Cell Pharmacol        ISSN: 1938-1247


  30 in total

1.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

2.  Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.

Authors:  Sahar M A Mahmoud; Emma Claire Paish; Desmond G Powe; R Douglas Macmillan; Matthew J Grainge; Andrew H S Lee; Ian O Ellis; Andrew R Green
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

3.  Elevated sphingomyelinase activity and ceramide concentration in serum of patients undergoing high dose spatially fractionated radiation treatment: implications for endothelial apoptosis.

Authors:  Sabapathi Sathishkumar; Boris Boyanovsky; Alexander A Karakashian; Krassimira Rozenova; Natalia V Giltiay; Mahesh Kudrimoti; Mohammed Mohiuddin; Mansoor M Ahmed; Mariana Nikolova-Karakashian
Journal:  Cancer Biol Ther       Date:  2005-09-13       Impact factor: 4.742

4.  Resistance of CD45RA- T cells to apoptosis and functional impairment, and activation of tumor-antigen specific T cells during radiation therapy of prostate cancer.

Authors:  Zsuzsanna Tabi; Lisa K Spary; Sharon Coleman; Aled Clayton; Malcolm D Mason; John Staffurth
Journal:  J Immunol       Date:  2010-06-14       Impact factor: 5.422

Review 5.  Accreditation and quality assurance for Radiation Therapy Oncology Group: Multicenter clinical trials using Stereotactic Body Radiation Therapy in lung cancer.

Authors:  Robert Timmerman; James Galvin; Jeff Michalski; William Straube; Geoffrey Ibbott; Elizabeth Martin; Ramzi Abdulrahman; Suzanne Swann; Jack Fowler; Hak Choy
Journal:  Acta Oncol       Date:  2006       Impact factor: 4.089

6.  Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival.

Authors:  Kelly G Paulson; Jayasri G Iyer; Andrew R Tegeder; Renee Thibodeau; Janell Schelter; Shinichi Koba; David Schrama; William T Simonson; Bianca D Lemos; David R Byrd; David M Koelle; Denise A Galloway; J Helen Leonard; Margaret M Madeleine; Zsolt B Argenyi; Mary L Disis; Juergen C Becker; Michele A Cleary; Paul Nghiem
Journal:  J Clin Oncol       Date:  2011-03-21       Impact factor: 44.544

7.  The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity.

Authors:  Byron C Burnette; Hua Liang; Youjin Lee; Lukasz Chlewicki; Nikolai N Khodarev; Ralph R Weichselbaum; Yang-Xin Fu; Sogyong L Auh
Journal:  Cancer Res       Date:  2011-02-07       Impact factor: 12.701

8.  Tumor response to radiotherapy regulated by endothelial cell apoptosis.

Authors:  Monica Garcia-Barros; Francois Paris; Carlos Cordon-Cardo; David Lyden; Shahin Rafii; Adriana Haimovitz-Friedman; Zvi Fuks; Richard Kolesnick
Journal:  Science       Date:  2003-05-16       Impact factor: 47.728

9.  Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer.

Authors:  Inga S Grills; Victor S Mangona; Robert Welsh; Gary Chmielewski; Erika McInerney; Shannon Martin; Jennifer Wloch; Hong Ye; Larry L Kestin
Journal:  J Clin Oncol       Date:  2010-01-11       Impact factor: 44.544

10.  Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial.

Authors:  David W Andrews; Charles B Scott; Paul W Sperduto; Adam E Flanders; Laurie E Gaspar; Michael C Schell; Maria Werner-Wasik; William Demas; Janice Ryu; Jean-Paul Bahary; Luis Souhami; Marvin Rotman; Minesh P Mehta; Walter J Curran
Journal:  Lancet       Date:  2004-05-22       Impact factor: 79.321

View more
  5 in total

1.  Spanish Society of Radiation Oncology clinical guidelines for stereotactic body radiation therapy in lymph node oligometastases.

Authors:  A J Conde-Moreno; J L Lopez-Guerra; V A Macias; M L Vázquez de la Torre; P Samper Ots; S San José-Maderuelo; J Pastor Peidro; J López-Torrecilla; J Expósito-Hernández
Journal:  Clin Transl Oncol       Date:  2015-09-02       Impact factor: 3.405

Review 2.  The Concept of Hormesis in Cancer Therapy - Is Less More?

Authors:  Andy Gaya; Charles A Akle; Satvinder Mudan; John Grange
Journal:  Cureus       Date:  2015-04-02

3.  Abscopal Effects: Case Report and Emerging Opportunities.

Authors:  Michael Lock; Ahmad Muinuddin; Walter I Kocha; Robert Dinniwell; George Rodrigues; David D'souza
Journal:  Cureus       Date:  2015-10-07

4.  Ablative Radiotherapy Reprograms the Tumor Microenvironment of a Pancreatic Tumor in Favoring the Immune Checkpoint Blockade Therapy.

Authors:  Yu-Hung Lee; Ching-Fang Yu; Ying-Chieh Yang; Ji-Hong Hong; Chi-Shiun Chiang
Journal:  Int J Mol Sci       Date:  2021-02-19       Impact factor: 5.923

5.  Impact of Pre-Treatment NLR and Other Hematologic Biomarkers on the Outcomes of Early-Stage Non-Small-Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy.

Authors:  Marina Aduquaye; Sheen Dube; Bashir Bashir; Amitava Chowdhury; Naseer Ahmed; Ahmet Leylek; Julian Kim; Pascal Lambert; Oliver Bucher; William Hunter; Gokulan Sivananthan; Rashmi Koul; Shrinivas Rathod
Journal:  Curr Oncol       Date:  2022-01-04       Impact factor: 3.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.